AI drug discovery: Where we are and where we’re going
The promise of AI in pharma is sprouting up across the business, from marketing to manufacturing to R&D. But one of the most game-changing areas – and one in which we've seen billions of dollars of investment – is drug discovery.
Exscientia is one of the first companies to make a mark in this space and one which boasts a successful IPO and partnerships with BMS, Sanofi, and Merck KGaA (Darmstadt, Germany), among others. And today’s guest is founder and CEO Andrew Hopkins, who has been named a top AI innovator by TIME and was recently appointed a lifetime fellow to both the Royal Society and the Academy of Medical Sciences in the UK.
Hopkins talks about how he got his start in the drug discovery space and why the intersection of AI and drug discovery is such an interdisciplinary field. He discusses how Exscientia’s approach has evolved from a singular focus to an end-to-end process for improving drug design and development with AI.
Hopkins and host Jonah Comstock also get into the increasingly competitive nature of the space and how to stay above the fray, keeping up with a rapidly innovative field, Hopkins’ “AI optimism”, and what the responsibilities are of an AI thought leader during this turbulent moment in the technology’s evolution.
Tune in for a wide-ranging conversation with one of the premier voices in pharmaceutical AI. And stay tuned for his 2024 predictions and advice for young innovators.
You can listen to episode 107 of the pharmaphorum podcast in the player below, download the episode to your computer, or find it – and subscribe to the rest of the series in iTunes, Spotify, acast, Stitcher, and Podbean.
